Literature DB >> 9918183

Management of facial nerve injury due to temporal bone trauma.

C Y Chang1, S P Cass.   

Abstract

OBJECTIVE: This article provides an overview of relevant data regarding the management of facial nerve injury due to temporal bone trauma. DATA SOURCES: Sources used were relevant English language clinical and basic science publications. STUDY SELECTION: A Medline search dating back to 1966 for articles concerning temporal bone trauma and facial nerve injury including both human and animal data was performed. Articles were included if they contained relevant data or were significant reviews on the subject. A retrograde bibliography search was then conducted to acquire any articles that may have been missed by the computerized search, including those papers published prior to 1966. DATA EXTRACTION: The data from each paper were reviewed individually. DATA SYNTHESIS: The data were not amenable to formal meta-analysis or valid data summarization.
CONCLUSIONS: Patients who should not require surgical intervention include those who have: documented normal facial nerve function after injury regardless of progression, presentation with incomplete facial nerve paralysis with no progression to complete paralysis, and degeneration <95% on ENoG. The remaining patients presumably have a poorer prognosis for return of facial nerve function although it remains unclear exactly how poor the return of function will be. Decompression surgery likely has a beneficial effect if performed within 14 days of injury, so those patients with expected poor natural outcomes may be offered this intervention. Late decompression surgery is not recommended. Late exploratory surgery is recommended only in those patients who do not experience adequate recovery of facial nerve function and likely require nerve repair. Despite the availability of a relatively large volume of published data, there remain many unanswered questions.

Entities:  

Mesh:

Year:  1999        PMID: 9918183

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  19 in total

Review 1.  [Traumatology of the ear and temporal bone].

Authors:  J P Thomas; A Minovi; S Dazert
Journal:  HNO       Date:  2011-12       Impact factor: 1.284

2.  Surgical approaches to facial nerve deficits.

Authors:  Craig Birgfeld; Peter Neligan
Journal:  Skull Base       Date:  2011-05

3.  High-velocity facial gunshot wounds: multidisciplinary care from prehospital to discharge.

Authors:  J D Sinnott; G Morris; P J Medland; K Porter
Journal:  BMJ Case Rep       Date:  2016-01-28

4.  [Estimating the prognosis of peripheral facial paralysis: is the minimal nerve excitability test still up to date?].

Authors:  G Psillas; J Constantinidis; A Printza; V Vital
Journal:  HNO       Date:  2007-08       Impact factor: 1.284

Review 5.  Facial nerve trauma: evaluation and considerations in management.

Authors:  Eli Gordin; Thomas S Lee; Yadranko Ducic; Demetri Arnaoutakis
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2015-03

6.  Chances of Improvement in Cases of Vestibular Schwannoma Presenting with Facial Nerve Weakness: Presentation of Two Cases and Literature Review.

Authors:  Ahmed R Rizk; Marcus Mehlitz; Martin Bettag
Journal:  J Neurol Surg B Skull Base       Date:  2018-07-03

7.  Management of temporal bone trauma.

Authors:  Alpen Patel; Eli Groppo
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2010-06

8.  Post Temporal Bone Fracture Facial Paralysis: Strategies in Decision Making and Analysis of Efficacy of Surgical Treatment.

Authors:  Deepika Vajpayee; Ajay Mallick; Awadhesh K Mishra
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-04-19

Review 9.  Treatment of Temporal Bone Fractures.

Authors:  Rodney C Diaz; Brian Cervenka; Hilary A Brodie
Journal:  J Neurol Surg B Skull Base       Date:  2016-06-02

10.  Surgery for post-traumatic facial paralysis: are we overdoing it?

Authors:  Sanjeev Yadav; Naresh Kumar Panda; Roshan Verma; Jaimanti Bakshi; Manish Modi
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-09-25       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.